Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Yi-Hsuan Lin,Yu-Yao Huang,Yi-Ling Wu,Cheng-Wei Lin,Pei-Chun Chen,Chee Jen Chang,Sheng-Hwu Hsieh,Jui-Hung Sun,Szu-Tah Chen,Chia-Hung Lin

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

2018

Yi-Hsuan Lin
Yu-Yao Huang
Yi-Ling Wu
Cheng-Wei Lin
Pei-Chun Chen
Chee Jen Chang
Sheng-Hwu Hsieh
Jui-Hung Sun
Szu-Tah Chen
Chia-Hung Lin

Background The effect of combined insulin and dipeptidyl peptidase-4 inhibitor (DPP4i) therapy on major adverse cardiovascular events (MACEs) in patients with diabetic foot is unclear.

Keywords:

Dipeptidyl peptidase-4
Insulin
Endocrinology
Diabetic foot
Population
Diabetes mellitus
Internal medicine
Medicine
Myocardial infarction
Lower risk
Cohort study
Propensity score matching
Heart failure

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations